Table 1 Baseline characteristics of haematology patients with acute respiratory failure
PCP (n = 13) | No-PCP (n = 128) | P value | |
|---|---|---|---|
Age, year | 54.0 (49.0–64.0) | 59.0 (49.0–65.0) | 0.585 |
Sex, male | 12 (92.3) | 78 (60.9) | 0.052 |
Underlying disease | |||
Myeloid disease | 0.896 | ||
Acute/chronic myeloid leukaemia | 4 (30.8) | 40 (31.2) | |
Myelodysplastic syndrome | 1 (7.7) | 16 (12.5) | |
Other myeloid disease | 1 (7.7) | 6 (4.7) | |
Lymphoproliferative disease | |||
Acute/ chronic lymphocytic leukaemia | 2 (15.4) | 21 (16.4) | |
Non-Hodgkin lymphoma | 4 (30.8) | 26 (20.3) | |
Myeloma | 0 (0.0) | 10 (7.8) | |
Hodgkin lymphoma | 0 (0.0) | 4 (3.1) | |
Others | 1 (7.7) | 5 (3.9) | |
Stem cell transplantation | 0.492 | ||
Allogenic | 2 (15.4) | 40 (31.2) | |
Autologous | 11 (7.7) | 8 (6.2) | |
Oncologic malignancy | 2 (15.4) | 4 (3.1) | 0.172 |
Steroid user | 0.740 | ||
High-dose steroids | 2 (15.4) | 32 (25.0) | |
More than 3 months | 2 (15.4) | 11 (8.6) | |
Within 1 month | 2 (15.4) | 14 (10.9) | |
Dose of steroid over the duration, mg (prednisolone equivalent) | 2155 (350–4000) | 2750 (900–5303) | 0.661 |
Duration, days | 48.0 (12.0–163.0) | 62.0 (25.0–165.0) | 0.566 |
Specific drugs | 0.084 | ||
T-cell immunosuppressors | 1 (14.3) | 32 (43.2) | |
Immune checkpoint inhibitor | 2 (28.6) | 4 (5.4) | |
Bactrim prophylaxis* | 0 (0.0) | 30 (23.4) | 0.107 |